Targeting the delivery of glycan-based paclitaxel prodrugs to cancer cells via glucose transporters

Journal of Medicinal Chemistry

Volumn 51, Issue 23, 2008, Pages 7428-7441

  Lin, Yih Shyan ^a,b   Tungpradit, Rudeewan ^a,c   Sinchaikul, Supachok ^a   An, Feng Ming ^a   Liu, Der Zen ^d   Phutrakul, Suree ^c   Chen, Shui Tein ^a,b  

^a INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c CHIANG MAI UNIVERSITY   (Thailand)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE TRANSPORTER; GLUCURONIC ACID; GLYCAN DERIVATIVE; PACLITAXEL DERIVATIVE; PRODRUG; TUBULIN;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL STRUCTURE; CHROMOSOME; CONJUGATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TRANSPORT; HUMAN; HUMAN CELL; NONHUMAN; REACTION ANALYSIS;

ANIMALS; CELL LINE; CELL PROLIFERATION; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; HUMANS; MOLECULAR STRUCTURE; PACLITAXEL; POLYSACCHARIDES; PRODRUGS; STEREOISOMERISM;

EID: 57349142938     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8006257     Document Type: Article

References (44)

1. Shen, S. I.; Kotamraj, P. R.; Bhattacharya, S.; Li, X.; Jasti, B. R. Synthesis and characterization of RGD-fatty acid amphiphilic micelles as targeted delivery carriers for anticancer agents. J. Drug Target 2007, 15, 51-58.
2. Mittal, S.; Song, X.; Vig, B. S.; Amidon, G. L. Proline prodrug of melphalan targeted to prolidase, a prodrug activating enzyme overexpressed in melanoma. Pharm. Res. 2007, 24, 1290-1298.
3. Sperker, B.; Werner, U.; Murdter, T. E.; Tekkaya, C.; Fritz, P.; Wacke, R.; Adam, U.; Gerken, M.; Drewelow, B.; Kroemer, H. K. Expression and function of beta-glucuronidase in pancreatic cancer: potential role in drug targeting. Naunyn-Schmiedeberg's Arch. Pharmacol. 2000, 362, 110-115.
4. Bosslet, K.; Straub, R.; Blumrich, M.; Czech, J.; Gerken, M.; Sperker, B.; Kroemer, H. K.; Gesson, J. P.; Koch, M.; Monneret, C. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res. 1998, 58, 1195-1201.
5. Islam, M. R.; Tomatsu, S.; Shah, G. N.; Grubb, J. H.; Jain, S.; Sly, W. S. Active site residues of human beta-glucuronidase. Evidence for Glu(540) as the nucleophile and Glu(451) as the acid-base residue. J. Biol. Chem. 1999, 274, 23451-23455.
6. Liu, D. Z.; Sinchaikul, S.; Reddy, P. V.; Chang, M. Y.; Chen, S. T. Synthesis of 2′-paclitaxel methyl 2-glucopyranosyl succinate for specific targeted delivery to cancer cells. Bioorg. Med. Chem. Lett. 2007, 17, 617-620.
7. Funasaka, T.; Yanagawa, T.; Hogan, V.; Raz, A. Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia. FASEB J. 2005, 19, 1422-1430.
8. Macheda, M. L.; Rogers, S.; Best, J. D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell. Physiol. 2005, 202, 654-662.
9. Ettmayer, P.; Amidon, G. L.; Clement, B.; Testa, B. Lessons learned from marketed and investigational prodrugs. J. Med. Chem. 2004, 47, 2393-2404.
10. Skwarczynski, M.; Hayashi, Y.; Kiso, Y. Paclitaxel prodrugs: toward smarter delivery of anticancer agents. J. Med. Chem. 2006, 49, 7253-7269.
11. Damen, E. W.; Nevalainen, T. J.; van den Bergh, T. J.; de Groot, F. M.; Scheeren, H. W. Synthesis of novel paclitaxel prodrugs designed for bioreductive activation in hypoxic tumour tissue. Bioorg. Med. Chem. 2002, 10, 71-77.
12. Abouzied, M. M.; Crawford, E. S.; Nabi, H. A. 18F-FDG imaging: pitfalls and artifacts. J. Nucl. Med. Technol. 2005, 33, 145-155.
13. Nguyen, X. C.; Lee, W. W.; Chung, J. H.; Park, S. Y.; Sung, S. W.; Kim, Y. K.; So, Y.; Lee, D. S.; Chung, J. K.; Lee, M. C.; Kim, S. E. FDG uptake, glucose transporter type 1, and Ki-67 expressions in nonsmall-cell lung cancer: correlations and prognostic values. Eur. J. Radiol. 2007, 62, 214-219.
14. Ferlini, C.; Ojima, I.; Distefano, M.; Gallo, D.; Riva, A.; Morazzoni, P.; Bombardelli, E.; Mancuso, S.; Scambia, G. Second generation taxanes: from the natural framework to the challenge of drug resistance. Curr. Med. Chem. Anticancer Agents 2003, 3, 133-138.
15. Nabholtz, J. M.; Vannetzel, J. M.; Llory, J. F.; Bouffette, P. Advances in the use of taxanes in the adjuvant therapy of breast cancer. Clin. Breast Cancer 2003, 4, 187-192.
16. Kumar, N. Taxol-induced polymerization of purified tubulin. Mechanism of action. J. Biol. Chem. 1981, 256, 10435-10441.
17. Parekh, H.; Simpkins, H. The transport and binding of taxol. Gen. Pharmacol. 1997, 29, 167-172.
18. Horwitz, S. B. Mechanism of action of taxol. Trends Pharmacol. Sci. 1992, 13, 134-136.
19. Rooseboom, M.; Commandeur, J. N.; Vermeulen, N. P. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol. Rev. 2004, 56, 53-102.
20. Abraham, S.; Guo, F.; Li, L. S.; Rader, C.; Liu, C.; Barbas, C. F.; Lerner, R. A.; Sinha, S. C. Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 5584-5589.
21. Chatterjee, S. K.; Zetter, B. R. Cancer biomarkers: knowing the present and predicting the future. Future Oncol. 2005, 1, 37-50.
22. de Graaf, M.; Boven, E.; Scheeren, H. W.; Haisma, H. J.; Pinedo, H. M. Beta-glucuronidase-mediated drug release. Curr. Pharm. Des. 2002, 8, 1391-1403.
23. Wu, J.; Liu, Q.; Lee, R. J. A folate receptor-targeted liposomal formulation for paclitaxel. Int. J. Pharm. 2006, 316, 148-153.
24. Prestwich, G. D.; Marecak, D. M.; Marecek, J. F.; Vercruysse, K. P.; Ziebell, M. R. Controlled chemical modification of hyaluronic acid: synthesis, applications, and biodegradation of hydrazide derivatives. J. Controlled Release 1998, 53, 93-103.
25. Jaracz, S.; Chen, J.; Kuznetsova, L. V.; Ojima, I. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg. Med. Chem. 2005, 13, 5043-5054.
26. Younes, M.; Brown, R. W.; Stephenson, M.; Gondo, M.; Cagle, P. T. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997, 80, 1046-1051.
27. Gleadle, J. M.; Ratcliffe, P. J. Induction of hypoxia-inducible factor-1, erythropoietin, vascular endothelial growth factor, and glucose transporter-1 by hypoxia: evidence against a regulatory role for Src kinase. Blood 1997, 89, 503-509.
28. Raval, R. R.; Lau, K. W.; Tran, M. G.; Sowter, H. M.; Mandriota, S. J.; Li, J. L.; Pugh, C. W.; Maxwell, P. H.; Harris, A. L.; Ratcliffe, P. J. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell. Biol. 2005, 25, 5675-5686.
29. Pandit-Taskar, N. Oncologic imaging in gynecologic malignancies. J. Nucl. Med. 2005, 46, 1842-1850.
30. Funasaka, T.; Yanagawa, T.; Hogan, V.; Raz, A. Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia. FASEB J. 2005, 19, 1422-1430.
31. Isa, A. Y.; Ward, T. H.; West, C. M.; Slevin, N. J.; Homer, J. J. Hypoxia in head and neck cancer. Br. J. Radiol. 2006, 79, 791-798.
32. Noguchi, Y.; Sato, S.; Marat, D.; Doi, C.; Yoshikawa, T.; Saito, A.; Ito, T.; Tsuburaya, A.; Yanuma, S. Glucose uptake in the human gastric cancer cell line, MKN28, is increased by insulin stimulation. Cancer Lett. 1999, 140, 69-74.
33. Paik, J. Y.; Lee, K. H.; Ko, B. H.; Choe, Y. S.; Choi, Y.; Kim, B. T. Nitric oxide stimulates 18F-FDG uptake in human endothelial cells through increased hexokinase activity and GLUT1 expression. J. Nucl. Med. 2005, 46, 365-370.
34. Sako, T.; Naraba, H.; Teraoka, H.; Kitagawa, T. The intrinsic structure of glucose transporter isoforms Glut1 and Glut3 regulates their differential distribution to detergent-resistant membrane domains in non-polarized mammalian cells. FEBS J. 2007, 274, 2843-2853.
35. Liu, X. J.; Yang, C.; Gupta, N.; Zuo, J.; Chang, Y. S.; Fang, F. D. Protein kinase C-zeta of GLUT4 translocation through actin remodeling in CHO cells. J. Mol. Med. 2007, 85, 851-861.
36. Nelson, J. A.; Falk, R. E. Phloridzin and phloretin inhibition of 2-deoxy-D-glucose uptake by tumor cells in vitro and in vivo. Anticancer Res. 1993, 13, 2293-2299.
37. Ferreira, I. A.; Mocking, A. I.; Urbanus, R. T.; Varlack, S.; Wnuk, M.; Akkerman, J. W. Glucose uptake via glucose transporter 3 by human platelets is regulated by protein kinase B. J. Biol. Chem. 2005, 280, 32625-32633.
38. Ericsson, A.; Hamark, B.; Powell, T. L.; Jansson, T. Glucose transporter isofrom 4 is expressed in the syncytiotrophoblast of first trimester human placenta. Hum. Reprod. 2005, 20, 521-530.
39. Flier, J. S.; Mueckler, M. M.; Usher, P.; Lodish, H. F. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987, 235, 1492-1495.
40. Kant, J.; Huang, S.; Wong, H.; Fairchild, C.; Vyas, D.; Farina, V. Studies toward structure-activity relationships of taxol®: synthesis and cytotoxicity of taxol® analogues with C-2′ modified phenylisoserine side chains. Bioorg. Med. Chem. Lett. 1993, 3, 2471-2474.
41. de Groot, F. M.; van Berkom, L. W.; Scheeren, H. W. Synthesis and biological evaluation of 2′-carbamate-linked and 2′-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin. J. Med. Chem. 2000, 43, 3093-3102.
42. Huang, C. M.; Wu, Y. T.; Chen, S. T. Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis. Chem. Biol. 2000, 7, 453-461.
43. Kovacs, P.; Csaba, G.; Pallinger, E.; Czaker, R. Effects of taxol treatment on the microtubular system and mitochondria of Tetrahymena. Cell Biol. Int. 2007, 31, 724-732.
44. Hartfield, P. J.; Mayne, G. C.; Murray, A. W. Ceramide induces apoptosis in PC12 cells. FEBS Lett. 1997, 401, 148-152.